Kursinformation
Aktuelle News
News Funktionen
Weitere Funktionen
13 September 2023
Imcyse SA
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
22 Juni 2023
Imcyse SA
Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis
1 März 2023
Imcyse SA
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
13 April 2022
Imcyse SA
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis
14 März 2022
Imcyse SA
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
13 Januar 2022
Imcyse SA
Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study